We are the Bracco Group and we operate in the Life Sciences field.
Amongst the world leaders in diagnostic imaging,
we operate in medical devices
and advanced systems for the administration of contrast agent,
as well as in health services.
We were first established in 1927 and have never stopped growing since. Today, we are a multinational operating in 100 different countries: a position we have achieved through hard work, quality and reliability, values on which we base the fair, responsible management of our Group and which we share with our collaborators.
Developing innovative solutions for the prevention and early identification of illnesses, to improve quality of life.
Operating on an international scale thanks to the direct presence of associates throughout the world and cutting edge know-how. To constantly innovate products, services and the expertise of our associates to offer our customers increasing added value.
Three business areas, a single identity
From research to marketing, we deal with contrast agents and solutions to improve the efficiency of diagnostic imaging, patient safety and cost efficiency. With Bracco Imaging, we hold a worldwide leadership position in the main diagnostic imaging methods.
Medical devices and administration of contrast media
We develop advanced systems for the administration of contrast agent in radiology and software to assist radiologists and monitor patient radiation doses. With ACIST Medical Systems, we lead the global market of systems for the injection of contrast agents for cardiology and radiology for diagnostics and surgery.
Health services: CDI
Through the Centro Diagnostico Italiano (CDI – Italian Diagnostics Centre) – the Lombardy network of multiple speciality outpatient healthcare facilities – we supply analysis, prevention, diagnosis, dental, rehabilitation and specialised therapy services. Founded in 1975, today the CDI numbers more than 800 specialists and more than 200,000 diagnostic procedures each year.
A year of great milestones: the business
In 2019, we grew, generating value, achieving consolidated turnover of 1.47 billion euros and increasing sales. But above all, the English Blue Earth Diagnostics has joined our Group.
With Blue Earth Diagnostics in precision medicine
One of the most important, significant milestones of our 2019: we have acquired Blue Earth Diagnostics, thereby implementing new paradigms of care for the diagnosis and treatment of patients and strengthening our presence in precision medicine and personalised diagnostics.
Another step in our strategy towards the future: with this acquisition, we will increase our range of highly innovative solutions and carry out research and development focused on the new needs of patients.